Skip to main content

Advertisement

Table 2 Medication usage in mild and moderate/severe seasonal allergic rhinitis patients

From: The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey

  SAR severity
Mild
(n = 254)
Moderate/severe (n = 746) Odds ratio (95 % CI) P value
Taking medication, n (%) 230 (90.6) 718 (96.2) 2.68 (1.45, 4.89) 0.0004
Oral medications, n (%) 184 (80.0 %) 605 (84.3 %) 1.34 (0.89, 1.98) 0.1322
Cetirizine 82 (44.6) 313 (51.7) 1.33 (0.94, 1.89) 0.0885
Loratadine 61 (33.2) 195 (32.2) 0.96 (0.67, 1.39) 0.8153
Chlorphenamine 61 (33.2) 178 (29.4) 0.84 (0.58, 1.22) 0.3349
Pseudoephedrine 14 (7.6) 92 (15.2) 2.18 (1.19, 4.25) 0.0081
Phenylephrine 7 (3.8) 33 (5.5) 1.46 (0.62, 3.97) 0.3716
Acrivastine 20 (10.9) 82 (13.6) 1.29 (0.75, 2.28) 0.3420
Levocetirizine 0 (0) 19 (3.1) 0.011
Fexofenadine 10 (5.4) 38 (6.3) 1.17 (0.56, 2.68) 0.6741
Desloratadine 3 (1.6) 24 (4.0) 2.49 (0.74, 13.06) 0.1651
Other 17 (9.2) 57 (9.4) 1.02 (0.57, 1.93) 0.9408
Nasal sprays, n (%) 134 (58.3 %) 479 (66.7 %) 1.44 (1.05, 1.97) 0.0196
Fluticasone propionate 96 (71.6) 338 (70.6) 0.95 (0.60, 1.47) 0.8083
Beclomethasone 33 (24.6) 110 (23.0) 0.91 (0.57, 1.48) 0.6875
Mometasone 4 (3.0) 31 (6.5) 2.25 (0.77, 8.92) 0.1241
Fluticasone furoate 4 (3.0) 12 (2.5) 0.89 (0.26, 3.84) 0.8401
Flunisolide 1 (0.8) 12 (2.5) 3.42 (0.50, 147.15) 0.2116
Budesonide 2 (1.5) 10 (2.1) 1.41 (0.29, 13.36) 0.6602
Ipratropium bromide 0 (0) 5 (1.0) 0.29
Other 18 (13.4) 48 (10.0) 0.72 (0.39, 1.36) 0.2600
Oxymetazoline 9 (6.7) 39 (8.1) 1.23 (0.57, 2.97) 0.5871
Azelastine 25 (18.7) 106 (22.1) 1.23 (0.75, 2.10) 0.3860
Ocular medications, n (%) 72 (31.3 %) 275 (38.3 %) 1.36 (0.98, 1.90) 0.0552
Sodium cromoglicate 14 (19.4) 82 (29.8) 1.76 (0.91, 3.61) 0.0798
Antazoline 12 (16.7) 50 (18.2) 1.11 (0.54, 2.44) 0.7651
Xylometazoline 9 (12.5) 36 (13.1) 1.05 (0.47, 2.62) 0.8943
Azelastine 3 (4.2) 13 (4.7) 1.14 (0.30, 6.41) 0.8400
Olopatadine 3 (4.2) 17 (6.2) 1.52 (0.42, 8.29) 0.5137
Lodoxamide trometamol 1 (1.4) 9 (3.3) 2.40 (0.32, 106.74) 0.3950
Other 33 (45.8) 98 (35.6) 0.65 (0.37, 1.15) 0.1121
Co-medicating, n (%) 129 (56.1) 506 (70.5) 1.87 (1.36, 2.56) 0.0001
Reported reason for co-medicating, n (%)
 More effective nasal treatment 55 (42.6) 295 (58.3) 1.88 (1.25, 2.84) 0.0014
 More effective ocular treatment 54 (41.9) 209 (41.3) 0.98 (0.65, 1.48) 0.9089
 Faster nasal response 22 (17.1) 116 (22.9) 1.45 (0.86, 2.52) 0.1490
 Faster ocular 13 (10.1) 57 (11.3) 1.13 (0.59, 2.33) 0.7007
 Other 18 (19.0) 48 (9.5) 0.65 (0.35, 1.23) 0.1378
  1. SAR severity: paricipants with moderate/severe AR were defined as those who scored a rTNSS ≥8 out of 12, including a congestion score ≥2/3, when describing their ‘worst symptoms’. Participants with mild AR included all remaining patient
  2. SAR seasonal allergic rhinitis, CI confidence interval